Evidence map›Paper›PMID 39952817›Full record

ArticleSeminars in oncology nursing2025

Greater Symptom Burden and Poorer Quality of Life Outcomes Are Associated With The Co-Occurrence of Anxiety and Depression During Cancer Chemotherapy.

Alejandra Calvo-Schimmel, Marilyn J Hammer, Yvette P Conley, Steven M Paul, Bruce A Cooper, Joosun Shin, Carolyn Harris, Lisa Morse, Jon D Levine, Christine Miaskowski

Abstract read
In one paragraph

Article in Seminars in oncology nursing, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alejandra Calvo-SchimmelAmerican Cancer Society, Atlanta, GA.
Marilyn J HammerDana Farber Cancer Institute, Boston, MA.
Yvette P ConleySchool of Nursing, University of Pittsburgh, Pittsburgh, PA.
Steven M PaulSchool of Nursing, University of California, San Francisco, CA.
Bruce A CooperSchool of Nursing, University of California, San Francisco, CA.
Joosun ShinDana Farber Cancer Institute, Boston, MA.
Carolyn HarrisSchool of Nursing, University of Pittsburgh, Pittsburgh, PA.
Lisa MorseSchool of Nursing, University of California, San Francisco, CA.
Jon D LevineSchool of Medicine, University of California, San Francisco, CA.
Christine MiaskowskiSchool of Nursing, University of California, San Francisco, CA; School of Medicine, University of California, San Francisco, CA. Electronic address: chris.miaskowski@ucsf.edu.

Funding

Symptoms Clusters in Oncology Patients Receiving ChemotherapyR01CA134900 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AOUIZERAT, BRADLEY E, MIASKOWSKI, CHRISTINE A. · 2009 to 2014
$5.9M
Biobehavioral Research Training Program in Symptom ScienceT32NR016920 · NINR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MIASKOWSKI, CHRISTINE A., WEISS, SANDRA JEAN · 2017 to 2021
$2.4M
Influence of Social Determinants of Health and Epigenomics on Psychological Symptom Cluster SeverityK99CA286967 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HARRIS, CAROLYN STIGGE · 2024 to 2025
$323k
NCI NIH HHS K99 CA286967NCI NIH HHS R01 CA134900NINR NIH HHS T32 NR016920
6 · The paper itself

Abstract

objectivesAnxiety and depression are common symptoms in oncology patients undergoing chemotherapy. Study purpose was to evaluate for differences in severity of common symptoms (ie, fatigue, energy, sleep disturbance, cognitive function, pain) and quality of life (QOL) outcomes among three subgroups of oncology outpatients with distinct joint anxiety and depression profiles.

methodsOncology outpatients (N = 1328) completed measures of state anxiety and depression, six times over two cycles of chemotherapy. Latent profile analysis was done to identify subgroups of patients with distinct joint state anxiety AND depression profiles. Patients completed measures of trait anxiety, morning and evening fatigue, morning and evening energy, sleep disturbance, cognitive function, and pain, as well as generic and disease-specific measures of QOL at enrollment. Differences among the classes in symptom severity scores and QOL scores were evaluated using parametric and non-parametric tests.

resultsThree distinct joint anxiety AND depression profiles were identified and named: Low Anxiety and Low Depression (57.5%, Both Low), Moderate Anxiety and Moderate Depression (33.7%, Both Moderate), and High Anxiety and High Depression (8.8%, Both High). All of the symptom severity scores showed a "dose-response effect" (ie, as the joint anxiety AND depression profiles worsened, the severity of all of the symptoms increased). Likewise, for both the general and disease-specific QOL (except spiritual well-being) measures, all of the scores decreased as the joint anxiety AND depression profiles worsened. Compared to the Both Low classes, the other two classes reported lower scores for the spiritual well-being domain.

conclusionsMore than 40% of patients receiving chemotherapy experience moderate to high levels of both anxiety AND depression. These patients report an extremely high symptom burden and significant decrements in all domains of QOL. IMPLICATIONS FOR NURSING PRACTICE: Clinicians need to perform comprehensive assessments of depression and anxiety and other common symptoms and QOL outcomes during chemotherapy. In addition, referrals for targeted interventions are needed to manage multiple symptoms and improve patients' QOL.

Indexed as

Antineoplastic AgentsAnxietyDepressionNeoplasmsQuality of LifeAdultAgedFemaleHumansMaleMiddle AgedSeverity of Illness IndexSymptom BurdenAntineoplastic AgentsAnxietyCancerChemotherapyDepressionLatent profile analysisQuality of life

Identifiers

PMID39952817
PMCPMC13156918

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.